Der multimorbide geriatrisch/osteologische Patient mit Niereninsuffizienz

Zusammenfassung

Chronische Niereninsuffizienz und Osteoporose sind Erkrankungen mit zunehmender Prävalenz, hoher Morbidität, verminderter Lebensqualität und steigender Mortalität. Darüber hinaus führt eine chronische Einschränkung der Nierenfunktion zu Störungen des Mineral- und Vitamin-D-Stoffwechsels und damit zu Knochenerkrankungen, die von einer Osteoporose abzugrenzen sind. Im Beitrag werden die Besonderheiten in der Diagnostik und Therapie der metabolischen Osteopathie bei chronischer Niereninsuffizienz zusammengefasst

Summary

Chronic kidney disease and osteoporosis are an increasing and international public health problem. It is strongly related to high morbidity, loss of quality of life and increasing mortality. Furthermore renal insufficiency causes disturbances in mineraland vitamin D metabolism and generates metabolic bone disease beside osteoporosis. This “bone and mineral disorder” requires special diagnostic and therapeutic approach.

Schlüsselwörter

Chronische Niereninsuffizienz - Osteoporose - Knochenumbau

Keywords

Renal insufficiency - osteoporosis - bone turnover

• Literatur

• 1 KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. In: Kidney Disease: Improving Global Outcomes [KDIGO] CKD Work Group Kidney international 2012; 01: 1-150.
• 2 Girndt M, Trocchi P, Scheidt-Nave C. et al. The Prevalence of Renal Failure. Results from the German Health Interview and Examination Survey for Adults, 2008–2011 (DEGS1). Deutsches Arzteblatt international 2016; 113 (06) 85-91.
• 3 Moe S, Drueke T, Cunningham J. et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney international 2006; 69 (11) 1945-1953.
• 4 Al Badr W, Martin KJ. Role of bone biopsy in renal osteodystrophy. Saudi journal of kidney diseases and transplantation 2009; 20 (01) 12-19.
• 5 Lehmann G, Ott U, Kaemmerer D. et al. Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease Stages 3 – 5. Clinical nephrology 2008; 70 (04) 296-305.
• 6 Cummings SR, Black DM, Nevitt MC. et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993; 341 8837 72-75.
• 7 Gerakis A, Hadjidakis D, Kokkinakis E. et al. Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. Journal of Nephrology 2000; 13 (06) 437-443.
• 8 Bucur RC, Panjwani DD, Turner L. et al. Low bone mineral density and fractures in stages 3–5 CKD: an updated systematic review and meta-analysis. Osteoporosis international 2015; 26 (02) 449-458.
• 9 Lehmann G, Ott U, Maiwald J, Wolf G. Bone histomorphometry after treatment with teriparatide (PTH 1–34) in a patient with adynamic bone disease subsequent to parathyroidectomy. NDT plus 2009; 02 (01) 49-51.
• 10 Jamal SA, Ljunggren O, Stehman-Breen C. et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of bone and mineral research 2011; 26 (08) 1829-1835.
• 11 Kidney Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group. Kidney international. 2009 113.